StreetInsider.com News Articles

Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex

Thu, 23 Jul 2026 08:55:00 -0400

— Milestone highlights growing adoption while underscoring that millions of women remain unaware they have a hormone-free prescription contraceptive choice —

SAN DIEGO--(BUSINESS WIRE)-- Women’s health innovator Evofem Biosciences, Inc. (OTCID: EVFM) today announced the shipment of its 500,000th box of PHEXX® (lactic acid, citric acid and potassium bitartrate), the first and only FDA-approved hormone-free, on-demand prescription contraceptive vaginal gel.

This milestone marks an important achievement for the company and reflects the growing number of women seeking contraception that aligns with their personal preferences, lifestyles, and healthcare needs. With 12 pre-filled PHEXX applicators per

Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex

Thu, 23 Jul 2026 08:55:00 -0400

— Milestone highlights growing adoption while underscoring that millions of women remain unaware they have a hormone-free prescription contraceptive choice —

Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex

Thu, 23 Jul 2026 08:55:00 -0400

— Milestone highlights growing adoption while underscoring that millions of women remain unaware they have a hormone-free prescription contraceptive choice —

Evofem Biosciences Celebrates Shipment of Its 500,000th Unit of PHEXX®, Representing Hormone-Free Protection from Unintended Pregnancy for 6 Million Acts of Sex

Thu, 23 Jul 2026 08:55:00 -0400

— Milestone highlights growing adoption while underscoring that millions of women remain unaware they have a hormone-free prescription contraceptive choice —

Form 8-K Evofem Biosciences, Inc. For: Jul 20

Mon, 20 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260720/26789869.html

Form 8-K Evofem Biosciences, Inc. For: Jul 20

Mon, 20 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260720/26789869.html

Form 8-K Evofem Biosciences, Inc. For: Jul 08

Tue, 14 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260714/26768645.html

Form 8-K Evofem Biosciences, Inc. For: Jul 08

Tue, 14 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260714/26768645.html

Evofem Biosciences (EVFM) Misses Q1 EPS by 4c

Mon, 18 May 2026 16:40:49 -0400

Evofem Biosciences (OTC: EVFM) reported Q1 EPS of ($0.04). Revenue for the quarter came in at $900 thousand.

For earnings history and earnings-related data on Evofem Biosciences (EVFM) click here.

Form 8-K Evofem Biosciences, Inc. For: May 18

Mon, 18 May 2026 08:56:00 -0400

si-local-file:///var/storage/secattach/20260518/26510969.html

Form 8-K Evofem Biosciences, Inc. For: May 18

Mon, 18 May 2026 08:56:00 -0400

si-local-file:///var/storage/secattach/20260518/26510969.html

Evofem Reports First Quarter 2026 Financial Results and Provides Business Update